Skip to main content
Erschienen in:

01.10.2005 | AUO

Hochrisikopatienten mit neu diagnostiziertem Prostatakarzinom

Stellenwert adjuvanter und neoadjuvanter Therapiekonzepte

verfasst von: Prof. Dr. J. M. Wolff

Erschienen in: Die Onkologie | Ausgabe 10/2005

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit neu diagnostiziertem frühem Prostatakarzinom und erhöhtem Rezidivrisiko werden durch eine rein lokale Behandlung in der Regel nicht geheilt. Wie die Therapiestrategie für einen optimalen Therapieerfolg — möglichst Heilung — aussehen sollte, ist Gegenstand der klinischen Prüfung. Klinische Studien weisen auf einen Überlebenszeitgewinn durch multimodale Therapiekonzepte hin. Im Fokus stehen die adjuvante Strahlentherapie nach radikaler Prostatektomie (RP) sowie der frühzeitige — adjuvante und/oder neoadjuvante — Einsatz von Hormon- und Chemotherapie. Unabhängig davon ist zu definieren, bei welchen Patienten ein erhöhtes Rezidivrisiko vorliegt.
Literatur
1.
Zurück zum Zitat D’Amico et al. (2001) Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166:2185–2188PubMed D’Amico et al. (2001) Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166:2185–2188PubMed
2.
Zurück zum Zitat D’Amico et al. (2003) Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. JCO 21 2163–2172 D’Amico et al. (2003) Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. JCO 21 2163–2172
3.
Zurück zum Zitat Freedland et al. and The SEARCH Database Study Group (2003) Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol 169:2136–2141CrossRefPubMed Freedland et al. and The SEARCH Database Study Group (2003) Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol 169:2136–2141CrossRefPubMed
4.
Zurück zum Zitat Trudel et al. (2003) Significance of MMP-2 expression in prostate cancer: An immunohistochemical study. Cancer Res 63:8511–8515PubMed Trudel et al. (2003) Significance of MMP-2 expression in prostate cancer: An immunohistochemical study. Cancer Res 63:8511–8515PubMed
5.
Zurück zum Zitat Partin et al. (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445–1451CrossRefPubMed Partin et al. (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445–1451CrossRefPubMed
6.
Zurück zum Zitat Kattan et al. (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. JCO 21:4568–4571CrossRef Kattan et al. (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. JCO 21:4568–4571CrossRef
7.
Zurück zum Zitat Graefen et al. (2002) International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. JCO 20:3206–3212CrossRef Graefen et al. (2002) International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. JCO 20:3206–3212CrossRef
8.
Zurück zum Zitat Clark et al. (2001) Intermediate term outcome with radical prostatectomy for localized prostate cancer: The Cleveland Clinic Experience. Prostate J 3:118–125CrossRef Clark et al. (2001) Intermediate term outcome with radical prostatectomy for localized prostate cancer: The Cleveland Clinic Experience. Prostate J 3:118–125CrossRef
9.
Zurück zum Zitat Lau et al. (2002) Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: tectomy for pathological variables. J Urol 117–122 Lau et al. (2002) Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: tectomy for pathological variables. J Urol 117–122
10.
Zurück zum Zitat Gerber et al. (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur Urol 385–390 Gerber et al. (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur Urol 385–390
11.
Zurück zum Zitat Vicini et al. (2002) An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 21:26–35 Vicini et al. (2002) An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 21:26–35
12.
Zurück zum Zitat Kupelian et al. (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33 Kupelian et al. (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33
13.
Zurück zum Zitat Pollack et al. (2002) Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105 Pollack et al. (2002) Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105
14.
Zurück zum Zitat D’Amico et al. (2002) Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology Suppl 60:32–38CrossRef D’Amico et al. (2002) Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology Suppl 60:32–38CrossRef
15.
Zurück zum Zitat Valicenti et al. (1999) The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: A matched-pair analysis. Int J Radiat Oncol Biol Phys 45:53–58 Valicenti et al. (1999) The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: A matched-pair analysis. Int J Radiat Oncol Biol Phys 45:53–58
16.
Zurück zum Zitat Bolla et al. (2004) Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). Proc Am Soc Clin Oncol 22:383(#4504) Bolla et al. (2004) Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). Proc Am Soc Clin Oncol 22:383(#4504)
17.
Zurück zum Zitat Bolla et al. (2004) Postoperative radiotherapy (P-RXT) after radical prostatectomy (Px) improves progression-free survival (PFS) in pT3N0 prostate cancer (PC) (EORTC 22911). Int J Radiat Oncol Biol Phys 60: S186 (#93) Bolla et al. (2004) Postoperative radiotherapy (P-RXT) after radical prostatectomy (Px) improves progression-free survival (PFS) in pT3N0 prostate cancer (PC) (EORTC 22911). Int J Radiat Oncol Biol Phys 60: S186 (#93)
18.
Zurück zum Zitat Van Poppel et al. (2003) Is immediate post-operative radiation of pT3N0 prostate cancer safe treatment? Results of EORTC-trial 22911. J Urol 169:#1843 Van Poppel et al. (2003) Is immediate post-operative radiation of pT3N0 prostate cancer safe treatment? Results of EORTC-trial 22911. J Urol 169:#1843
19.
Zurück zum Zitat Formenti et al. (2000) Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy. Urology 56:453–458CrossRefPubMed Formenti et al. (2000) Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy. Urology 56:453–458CrossRefPubMed
20.
Zurück zum Zitat Kirk et al. (2000) Immediate vs deferred hormone treatment for prostate cancer: How safe is androgen deprivation? Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol Suppl 86:220 Kirk et al. (2000) Immediate vs deferred hormone treatment for prostate cancer: How safe is androgen deprivation? Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol Suppl 86:220
21.
Zurück zum Zitat The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 79:235–246PubMed The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 79:235–246PubMed
22.
Zurück zum Zitat Bolla et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360:103–108CrossRefPubMed Bolla et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360:103–108CrossRefPubMed
23.
Zurück zum Zitat Pilepich et al. (2003) Phase III-trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85–31. Proc Am Soc Clin Oncol 22:381A Pilepich et al. (2003) Phase III-trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85–31. Proc Am Soc Clin Oncol 22:381A
24.
Zurück zum Zitat Granfors et al. (1998) Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol 159:2020–2034 Granfors et al. (1998) Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol 159:2020–2034
25.
Zurück zum Zitat D’Amico et al. (2004) 6 month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821–827CrossRefPubMed D’Amico et al. (2004) 6 month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821–827CrossRefPubMed
26.
Zurück zum Zitat Messing et al. (1999) immediate hormonal therapy vs. observations in men with node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: A randomized phase III Eastern Cooperative Oncology Group/Intergroup Trial. NEJM 341:1781–1788CrossRefPubMed Messing et al. (1999) immediate hormonal therapy vs. observations in men with node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: A randomized phase III Eastern Cooperative Oncology Group/Intergroup Trial. NEJM 341:1781–1788CrossRefPubMed
27.
Zurück zum Zitat Messing et al. (2004) immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. J Urol 171:383 Messing et al. (2004) immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. J Urol 171:383
28.
Zurück zum Zitat Peta et al. (2003) Prostate Cancer Trialists Cooperative Group, presentation by the 2003 EMBO Conference Peta et al. (2003) Prostate Cancer Trialists Cooperative Group, presentation by the 2003 EMBO Conference
29.
Zurück zum Zitat Iversen et al. (2004) Bicalutamide vs placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median follow-up from Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004, 172:1871–1876 Iversen et al. (2004) Bicalutamide vs placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median follow-up from Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004, 172:1871–1876
30.
Zurück zum Zitat Han et al. (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-Year Johns Hopkins Experience. Urol Clin NA 28:555CrossRef Han et al. (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-Year Johns Hopkins Experience. Urol Clin NA 28:555CrossRef
31.
Zurück zum Zitat Hull et al. (2002) Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 167:528–534CrossRefPubMed Hull et al. (2002) Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 167:528–534CrossRefPubMed
32.
Zurück zum Zitat Partin et al. (2004) Prostatic specific antigen doubling time after radical prostatectomy as a predictor of cause specific survival. J Urol 171:382 Partin et al. (2004) Prostatic specific antigen doubling time after radical prostatectomy as a predictor of cause specific survival. J Urol 171:382
33.
Zurück zum Zitat Cadeddu et al. (2000) Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 164:1322–2133PubMed Cadeddu et al. (2000) Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 164:1322–2133PubMed
34.
Zurück zum Zitat Leventis et al. (2001) Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. JCO 19:2109 Leventis et al. (2001) Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. JCO 19:2109
35.
Zurück zum Zitat Dreicer et al. (2004) Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63:1138–1142CrossRefPubMed Dreicer et al. (2004) Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63:1138–1142CrossRefPubMed
36.
Zurück zum Zitat Oh et al. (2001) Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. Semin Oncol Suppl 15 28:40–44 Oh et al. (2001) Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. Semin Oncol Suppl 15 28:40–44
37.
Zurück zum Zitat Eastham et al. (2003) Cancer and leukemia group (CALGB) 90203: A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostetctomy for patients with high-risk localized disease. Urol Suppl 6B 62:55–62 Eastham et al. (2003) Cancer and leukemia group (CALGB) 90203: A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostetctomy for patients with high-risk localized disease. Urol Suppl 6B 62:55–62
38.
Zurück zum Zitat Wang et al. (2000) Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. Br J Urol Int, 86:675–680 Wang et al. (2000) Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. Br J Urol Int, 86:675–680
39.
Zurück zum Zitat Rosenbaum et al. (2005) A pilot multicenter phase II study of adjuvant Docetaxel (D) for high risk prostate cancer (PC) patients (pts.) after radical prostatectomy (RP): Preliminary data. Proc Am Soc Clin Oncol 23:394 s, #4565 Rosenbaum et al. (2005) A pilot multicenter phase II study of adjuvant Docetaxel (D) for high risk prostate cancer (PC) patients (pts.) after radical prostatectomy (RP): Preliminary data. Proc Am Soc Clin Oncol 23:394 s, #4565
Metadaten
Titel
Hochrisikopatienten mit neu diagnostiziertem Prostatakarzinom
Stellenwert adjuvanter und neoadjuvanter Therapiekonzepte
verfasst von
Prof. Dr. J. M. Wolff
Publikationsdatum
01.10.2005
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 10/2005
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-005-0954-x

Weitere Artikel der Ausgabe 10/2005

Der Onkologe 10/2005 Zur Ausgabe

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.